Virological outcomes and risk factors for non-suppression for routine and repeat viral load testing after enhanced adherence counselling during viral load testing scale-up in Zimbabwe: analytic cross-sectional study using laboratory data from 2014 to 2018.
ART
HIV viral load testing
Implementation
Viral load non-suppression
Zimbabwe
Journal
AIDS research and therapy
ISSN: 1742-6405
Titre abrégé: AIDS Res Ther
Pays: England
ID NLM: 101237921
Informations de publication
Date de publication:
09 07 2022
09 07 2022
Historique:
received:
31
12
2021
accepted:
22
06
2022
entrez:
9
7
2022
pubmed:
10
7
2022
medline:
14
7
2022
Statut:
epublish
Résumé
Since the scale-up of routine viral load (VL) testing started in 2016, there is limited evidence on VL suppression rates under programmatic settings and groups at risk of non-suppression. We conducted a study to estimate VL non-suppression (> 1000 copies/ml) and its risk factors using "routine" and "repeat after enhanced adherence counselling (EAC)" VL results. We conducted an analytic cross-sectional study using secondary VL testing data collected between 2014 and 2018 from a centrally located laboratory. We analysed data from routine tests and repeat tests after an individual received EAC. Our outcome was viral load non-suppression. Bivariable and multivariable logistic regression was performed to identify factors associated with having VL non-suppression for routine and repeat VL. We analysed 103,609 VL test results (101,725 routine and 1884 repeat test results) collected from the country's ten provinces. Of the 101,725 routine and 1884 repeat VL tests, 13.8% and 52.9% were non-suppressed, respectively. Only one in seven (1:7) of the non-suppressed routine VL tests had a repeat test after EAC. For routine VL tests; males (vs females, adjusted odds ratio (aOR) = 1.19, [95% CI 1.14-1.24]) and adolescents (10-19 years) (vs adults (25-49 years), aOR = 3.11, [95% CI 2.9-3.31]) were more at risk of VL non-suppression. The patients who received care at the secondary level (vs primary, aOR = 1.21, [95% CI 1.17-1.26]) and tertiary level (vs primary, aOR = 1.63, [95% CI 1.44-1.85]) had a higher risk of VL non-suppression compared to the primary level. Those that started ART in 2014-2015 (vs < 2010, aOR = 0.83, [95% CI 0.79-0.88]) and from 2016 onwards (vs < 2010, aOR = 0.84, [95% CI 0.79-0.89]) had a lower risk of VL non-suppression. For repeat VL tests; young adults (20-24 years) (vs adults (25-49 years), (aOR) = 3.48, [95% CI 2.16 -5.83]), adolescents (10-19 years) (vs adults (25-49 years), aOR = 2.76, [95% CI 2.11-3.72]) and children (0-9 years) (vs adults (25-49 years), aOR = 1.51, [95% CI 1.03-2.22]) were at risk of VL non-suppression. Close to 90% suppression in routine VL shows that Zimbabwe is on track to reach the third UNAIDS target. Strategies to improve the identification of clients with high routine VL results for repeating testing after EAC and ART adherence in subpopulations (men, adolescents and young adolescents) at risk of viral non-suppression should be prioritised.
Sections du résumé
BACKGROUND
Since the scale-up of routine viral load (VL) testing started in 2016, there is limited evidence on VL suppression rates under programmatic settings and groups at risk of non-suppression. We conducted a study to estimate VL non-suppression (> 1000 copies/ml) and its risk factors using "routine" and "repeat after enhanced adherence counselling (EAC)" VL results.
METHODS
We conducted an analytic cross-sectional study using secondary VL testing data collected between 2014 and 2018 from a centrally located laboratory. We analysed data from routine tests and repeat tests after an individual received EAC. Our outcome was viral load non-suppression. Bivariable and multivariable logistic regression was performed to identify factors associated with having VL non-suppression for routine and repeat VL.
RESULTS
We analysed 103,609 VL test results (101,725 routine and 1884 repeat test results) collected from the country's ten provinces. Of the 101,725 routine and 1884 repeat VL tests, 13.8% and 52.9% were non-suppressed, respectively. Only one in seven (1:7) of the non-suppressed routine VL tests had a repeat test after EAC. For routine VL tests; males (vs females, adjusted odds ratio (aOR) = 1.19, [95% CI 1.14-1.24]) and adolescents (10-19 years) (vs adults (25-49 years), aOR = 3.11, [95% CI 2.9-3.31]) were more at risk of VL non-suppression. The patients who received care at the secondary level (vs primary, aOR = 1.21, [95% CI 1.17-1.26]) and tertiary level (vs primary, aOR = 1.63, [95% CI 1.44-1.85]) had a higher risk of VL non-suppression compared to the primary level. Those that started ART in 2014-2015 (vs < 2010, aOR = 0.83, [95% CI 0.79-0.88]) and from 2016 onwards (vs < 2010, aOR = 0.84, [95% CI 0.79-0.89]) had a lower risk of VL non-suppression. For repeat VL tests; young adults (20-24 years) (vs adults (25-49 years), (aOR) = 3.48, [95% CI 2.16 -5.83]), adolescents (10-19 years) (vs adults (25-49 years), aOR = 2.76, [95% CI 2.11-3.72]) and children (0-9 years) (vs adults (25-49 years), aOR = 1.51, [95% CI 1.03-2.22]) were at risk of VL non-suppression.
CONCLUSION
Close to 90% suppression in routine VL shows that Zimbabwe is on track to reach the third UNAIDS target. Strategies to improve the identification of clients with high routine VL results for repeating testing after EAC and ART adherence in subpopulations (men, adolescents and young adolescents) at risk of viral non-suppression should be prioritised.
Identifiants
pubmed: 35810317
doi: 10.1186/s12981-022-00458-z
pii: 10.1186/s12981-022-00458-z
pmc: PMC9270749
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
34Informations de copyright
© 2022. The Author(s).
Références
BMC Infect Dis. 2017 May 3;17(1):326
pubmed: 28468608
J Int AIDS Soc. 2017 Nov;20 Suppl 7:
pubmed: 29130621
Ther Clin Risk Manag. 2020 Mar 04;16:169-180
pubmed: 32184609
BMC Infect Dis. 2019 Jan 3;19(1):8
pubmed: 30606128
J Int AIDS Soc. 2020 Apr;23(4):e25479
pubmed: 32319203
J Adv Nurs. 2005 Mar;49(6):616-23
pubmed: 15737222
BMC Pediatr. 2010 Oct 17;10:74
pubmed: 20950492
AIDS Res Treat. 2020 Apr 21;2020:8909232
pubmed: 32373359
PLoS One. 2013 Jul 23;8(7):e70254
pubmed: 23894625
J Int AIDS Soc. 2020 Mar;23(3):e25458
pubmed: 32128964
PLoS One. 2018 Nov 9;13(11):e0200242
pubmed: 30412576
Trop Med Int Health. 2018 May;23(5):526-532
pubmed: 29505108
J Acquir Immune Defic Syndr. 2017 Nov 1;76(3):e87-e89
pubmed: 28708812
Health Policy Plan. 2000 Dec;15(4):432-40
pubmed: 11124247
HIV AIDS (Auckl). 2021 Aug 16;13:823-828
pubmed: 34429660
PLoS One. 2019 Feb 5;14(2):e0211326
pubmed: 30721229
PLoS One. 2021 Jan 22;16(1):e0245720
pubmed: 33481931
PLoS One. 2017 Jan 20;12(1):e0169651
pubmed: 28107430
Milbank Q. 2005;83(3):457-502
pubmed: 16202000
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
Public Health Action. 2019 Dec 21;9(4):177-181
pubmed: 32042612
AIDS Res Ther. 2019 Jan 21;16(1):2
pubmed: 30665440
J Int AIDS Soc. 2019 Oct;22(10):e25403
pubmed: 31686432
Public Health Action. 2020 Sep 21;10(3):92-96
pubmed: 33134122
J Int AIDS Soc. 2009 May 06;12:6
pubmed: 19419543
BMC Infect Dis. 2018 Sep 18;18(1):469
pubmed: 30227831
Int J Equity Health. 2022 Mar 27;21(1):42
pubmed: 35346208
AIDS Res Ther. 2018 Nov 17;15(1):20
pubmed: 30445984
PLoS One. 2019 Dec 3;14(12):e0225476
pubmed: 31794561
PLoS One. 2015 Feb 19;10(2):e0116144
pubmed: 25695494
PLoS One. 2017 Oct 24;12(10):e0186726
pubmed: 29065149
PLoS One. 2020 May 5;15(5):e0232576
pubmed: 32369504
BMC Public Health. 2018 Aug 22;18(1):1048
pubmed: 30134880
J Int AIDS Soc. 2017 Nov;20 Suppl 7:
pubmed: 29171180
F1000Res. 2020 Mar 16;9:191
pubmed: 32399206
J Int AIDS Soc. 2017 Nov;20 Suppl 7:
pubmed: 29171190
J Int AIDS Soc. 2019 Nov;22(11):e25415
pubmed: 31746541
J Int AIDS Soc. 2019 Aug;22(8):e25393
pubmed: 31454178
BMC Infect Dis. 2020 Jan 2;20(1):4
pubmed: 31898535
Int J STD AIDS. 2018 May;29(6):603-610
pubmed: 29334886
N Engl J Med. 2015 Aug 27;373(9):808-22
pubmed: 26193126
AIDS. 2014 Mar;28 Suppl 2:S161-9
pubmed: 24849476
J Acquir Immune Defic Syndr. 2010 Jan;53(1):86-94
pubmed: 20035164
AIDS Behav. 2020 Oct;24(10):2797-2810
pubmed: 32152815